Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company's development of ocular tissue rejuvenation therapeutics MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire/ — Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic products as an advisor to the company. A board-certified ophthalmologist and fellowship-trained specialist in oculoplastic and orbital surgery, Wu's academic work has focused on developing treatments for vision loss and eye disease.

http://www.padovanews.it/2022/08/23/prominent-ophthalmologist-will-guide-turn-bios-search-for-therapies-to-cure-eye-diseases/

#padovanews